-
公开(公告)号：US20110009600A1
公开(公告)日：2011-01-13
申请号：US12829836
申请日：2010-07-02
申请人： Kenya SHITARA , Rinpei Niwa , Akito Natsume
发明人： Kenya SHITARA , Rinpei Niwa , Akito Natsume
IPC分类号： C07K16/46
CPC分类号： C07K16/462 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 本发明涉及具有比人IgG1抗体和人IgG3抗体更高的补体依赖性细胞毒活性的重组抗体组合物，其中包含人IgG1抗体的Fc区中的CH2结构域的多肽被包含 氨基酸序列对应于如Kabat等人的欧盟指数所示的人IgG3抗体的相同位置; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
2.发明申请GENETICALLY RECOMBINANT ANTIBODY COMPOSITION CAPABLE OF BINDING SPECIFICALLY TO GANGLIOSIDE GM2 审中-公开具有特异性结合GANIOSIDE GM2的基因重组抗体组合物公开(公告)号：US20110236374A1
公开(公告)日：2011-09-29
申请号：US12524215
申请日：2008-01-24
申请人： Kenya Shitara , Rinpei Niwa , Akito Natsume
发明人： Kenya Shitara , Rinpei Niwa , Akito Natsume
IPC分类号： A61K39/395 , C12N5/10 , C07K16/18 , C07H21/04 , A61P35/00
CPC分类号： C07K16/44 , C07K16/2887 , C07K2317/41 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to a genetically recombinant antibody composition which specifically binds to ganglioside GM2, which has higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 本发明涉及特异性结合神经节苷脂GM2的遗传重组抗体组合物，神经节苷脂GM2比人IgG1抗体和人IgG3抗体具有更高的补体依赖性细胞毒活性，其中包含人Fc区中的CH2结构域的多肽 IgG1抗体被包含与Kabat等人所指示的EU指数所示的人IgG3抗体相同位置的氨基酸序列的多肽代替; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
公开(公告)号：US07994290B2
公开(公告)日：2011-08-09
申请号：US12019160
申请日：2008-01-24
申请人： Kenya Shitara , Rinpei Niwa , Akito Natsume
发明人： Kenya Shitara , Rinpei Niwa , Akito Natsume
CPC分类号： C07K16/2887 , A61K2039/505 , C07K16/00 , C07K16/2893 , C07K2317/24 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2319/00
摘要： The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 本发明涉及一种重组抗体组合物，其是人IgG1抗体，其包含CH2结构域，其中由Kabat等人在EU指数表示的位置276和339处的氨基酸。 被替换为其他氨基酸，并且在氨基酸被替换之前具有比包含CH2结构域的抗体更好的补体依赖性细胞毒活性; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将DNA引入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
公开(公告)号：US20090004186A1
公开(公告)日：2009-01-01
申请号：US12019160
申请日：2008-01-24
申请人： Kenya SHITARA , Rinpei NIWA , Akito NATSUME
发明人： Kenya SHITARA , Rinpei NIWA , Akito NATSUME
CPC分类号： C07K16/2887 , A61K2039/505 , C07K16/00 , C07K16/2893 , C07K2317/24 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2319/00
摘要： The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 本发明涉及一种重组抗体组合物，其是人IgG1抗体，其包含CH2结构域，其中由Kabat等人在EU指数表示的位置276和339处的氨基酸。 被替换为其他氨基酸，并且在氨基酸被替换之前具有比包含CH2结构域的抗体更好的补体依赖性细胞毒活性; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将DNA引入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
公开(公告)号：US20070148165A1
公开(公告)日：2007-06-28
申请号：US11491501
申请日：2006-07-24
申请人： Kenya Shitara , Rinpei Niwa , Akito Natsume
发明人： Kenya Shitara , Rinpei Niwa , Akito Natsume
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/462 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 本发明涉及具有比人IgG1抗体和人IgG3抗体更高的补体依赖性细胞毒活性的重组抗体组合物，其中包含人IgG1抗体的Fc区中的CH2结构域的多肽被包含 氨基酸序列对应于如Kabat等人的欧盟指数所示的人IgG3抗体的相同位置; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
公开(公告)号：US07923538B2
公开(公告)日：2011-04-12
申请号：US11491501
申请日：2006-07-24
申请人： Kenya Shitara , Rinpei Niwa , Akito Natsume
发明人： Kenya Shitara , Rinpei Niwa , Akito Natsume
IPC分类号： C12P21/08
CPC分类号： C07K16/462 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 本发明涉及具有比人IgG1抗体和人IgG3抗体更高的补体依赖性细胞毒活性的重组抗体组合物，其中包含人IgG1抗体的Fc区中的CH2结构域的多肽被包含 氨基酸序列对应于如Kabat等人的欧盟指数所示的人IgG3抗体的相同位置; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
公开(公告)号：US08883981B2
公开(公告)日：2014-11-11
申请号：US12829836
申请日：2010-07-02
申请人： Kenya Shitara , Rinpei Niwa , Akito Natsume
发明人： Kenya Shitara , Rinpei Niwa , Akito Natsume
CPC分类号： C07K16/462 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 本发明涉及具有比人IgG1抗体和人IgG3抗体更高的补体依赖性细胞毒活性的重组抗体组合物，其中包含人IgG1抗体的Fc区中的CH2结构域的多肽被包含 氨基酸序列对应于如Kabat等人的欧盟指数所示的人IgG3抗体的相同位置; 编码重组抗体组合物中所含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
公开(公告)号：US08492526B2
公开(公告)日：2013-07-23
申请号：US13166487
申请日：2011-06-22
申请人： Kenya Shitara , Rinpei Niwa , Akito Natsume
发明人： Kenya Shitara , Rinpei Niwa , Akito Natsume
IPC分类号： C07K16/00
CPC分类号： C07K16/2887 , A61K2039/505 , C07K16/00 , C07K16/2893 , C07K2317/24 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2319/00
摘要： Disclosed are a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 公开了一种重组抗体组合物，其是人IgG1抗体，其包含CH2结构域，其中如Kabat等人所述，由EU指数表示的位置276和339处的氨基酸。 被替换为其他氨基酸，并且在氨基酸被替换之前具有比包含CH2结构域的抗体更好的补体依赖性细胞毒活性; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将DNA引入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
公开(公告)号：US20120022238A1
公开(公告)日：2012-01-26
申请号：US13166487
申请日：2011-06-22
申请人： Kenya SHITARA , Rinpei NIWA , Akito NATSUME
发明人： Kenya SHITARA , Rinpei NIWA , Akito NATSUME
CPC分类号： C07K16/2887 , A61K2039/505 , C07K16/00 , C07K16/2893 , C07K2317/24 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2319/00
摘要： Disclosed are a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 公开了一种重组抗体组合物，其是人IgG1抗体，其包含CH2结构域，其中如Kabat等人所述，由EU指数表示的位置276和339处的氨基酸。 被替换为其他氨基酸，并且在氨基酸被替换之前具有比包含CH2结构域的抗体更好的补体依赖性细胞毒活性; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将DNA引入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
公开(公告)号：US20080241884A1
公开(公告)日：2008-10-02
申请号：US10575261
申请日：2004-10-08
申请人： Kenya Shitara , Emi Hosaka , Akito Natsume , Masako Wakitani , Kazuhisa Uchida , Mitsuo Satoh , Naoko Ohnuki , Kazuyasu Nakamura
发明人： Kenya Shitara , Emi Hosaka , Akito Natsume , Masako Wakitani , Kazuhisa Uchida , Mitsuo Satoh , Naoko Ohnuki , Kazuyasu Nakamura
CPC分类号： C07K16/30 , A61K38/00 , C07K14/70528 , C07K14/7151 , C07K16/00 , C07K16/3092 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/622 , C07K2317/72 , C07K2317/732 , C07K2319/00 , C07K2319/30 , C07K2319/32 , C12N9/1051 , C12N9/88 , C12N9/90
摘要： A fusion protein composition of an antibody Fc region which is useful as a medicament in which effector function is improved is desired.The present invention provides a fusion protein composition comprising a fusion protein molecule of an antibody Fc region having complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant producing the fusion protein composition; a process for producing the fusion protein composition; and a medicament comprising the fusion protein composition.
摘要翻译： 需要可用作改善效应子功能的药物的抗体Fc区的融合蛋白组合物。 本发明提供了融合蛋白组合物，其包含Fc区中具有复合型N-糖苷连接的糖链的抗体Fc区的融合蛋白分子，其中复合型N-糖苷连接的糖链具有其中岩藻糖 在糖链的还原末端不与N-乙酰氨基葡萄糖结合; 产生融合蛋白组合物的转化体; 制备融合蛋白组合物的方法; 和包含该融合蛋白组合物的药物。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.037 秒)
